NEW YORK (GenomeWeb) – Recent publications and company comments suggest diagnostics firm Biodesix is shifting its strategy around its Veristrat lung cancer test.

The firm has historically marketed the test with a focus on its predictive capabilities, particularly around patient response to tyrosine kinase inhibitors (TKIs) targeting EGFR.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

Already a 360Dx Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.